Beatson West of Scotland Cancer Centre

What Beatson West of Scotland Cancer Centre does

The Beatson West of Scotland Cancer Centre (BWoSCC) is a public, government-state healthcare facility operating as the regional specialist cancer centre for the West of Scotland under NHS Scotland governance. Founded in 1886 and based in Glasgow, the centre provides comprehensive oncology services including radiotherapy, chemotherapy, brachytherapy, palliative care, clinical trials, and diagnostic imaging (PET CT and MRI), along with supportive services such as clinical psychology, dietetics, spiritual care, and counselling. Patient access is delivered exclusively through NHS Scotland referral pathways on a publicly funded basis at the point of delivery, with no private pricing model in operation. The facility is organised into specialised inpatient wards (B1–B7), a Haematology Day Unit (B8), an Oncology Day Unit (B9), an Acute Oncology Assessment Unit, and an Enhanced Care Unit, plus dedicated services for Teenage and Young Adults (TYA, ages 13–24) and the Cancer Older Peoples Service (COPS).

The centre's product portfolio spans treatment modalities (radiotherapy with treatment planning, imaging, and radiotherapy physics; brachytherapy; chemotherapy), diagnostic services (PET CT, MRI), a Clinical Apheresis Unit (photopheresis, lymphocyte donation, PBSC collection), and a clinical trials programme. Underlying technical infrastructure includes radiotherapy treatment planning systems, mould room fabrication, and imaging platforms typical of tertiary oncology centres. The centre collaborates operationally with Beatson Cancer Charity (which funds the on-site Wellbeing Centre) and Macmillan Cancer Support, and in October 2025 was included among NHS Scotland facilities approved to deliver GSK's Blenrep combination therapy for relapsed or refractory multiple myeloma following Scottish Medicines Consortium approval.

The business model is non-commercial: as a government-state entity, the centre is funded through NHS Scotland block allocations and Scottish Government health budgets. There is no revenue-generating model, no private equity or venture capital ownership, and no IPO status. GTM motion is effectively community- and referral-led through NHS Scotland regional pathways. The centre's strategic value lies in its statutory regional designation as the principal cancer facility for the West of Scotland, providing integrated specialist services that no competing provider in the region replicates at equivalent scale.

Name

Beatson West of Scotland Cancer Centre

Legal name

Beatson West Of Scotland Cancer Centre

Website

https://beatson.scot.nhs.uk

Company type

Public

Founded year

1886

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The Beatson West of Scotland Cancer Centre is an NHS Scotland public hospital in Glasgow serving as the regional specialist cancer treatment facility for the West of Scotland, providing radiotherapy, chemotherapy, brachytherapy, diagnostics, and clinical trials via NHS referral pathways.

Ownership category

akta.pro rank

Product category

Cancer Treatment / Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Diagnostic Imaging Centers (621512), Ambulatory Health Care Services (621)

SIC

Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Hospital-Based Palliative Care (Inpatient Consult Services) (HLADAHAG)

Keywords

• Cancer treatment services
• Oncology radiotherapy
• Chemotherapy services
• Clinical trials oncology
• Palliative care

Headquarters

HQ city

Glasgow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

The Beatson West of Scotland Cancer Centre is the regional NHS Scotland specialist cancer centre for the West of Scotland, providing comprehensive oncology services including radiotherapy, chemotherapy, brachytherapy, PET CT and MRI diagnostics, clinical trials, and palliative care. It delivers inpatient, outpatient, and day-patient care across multiple specialized wards and units, along with supportive services such as psychology, counselling, dietetics, and spiritual care.

Product overview

Beatson West of Scotland Cancer Centre is a NHS Scotland cancer treatment facility providing comprehensive oncology services. The centre operates as a single unified hospital with multiple specialized departments offering cancer treatment across multiple modalities. Services include inpatient wards (B1-B7), day units for haematology and oncology, radiotherapy, chemotherapy, brachytherapy, diagnostic imaging (PET CT, MRI), clinical trials, and comprehensive support services including palliative care, psychology, dietetics, and spiritual care. The centre also provides specialized services for teenagers and young adults (TYA) and older peoples cancer services (COPS). The facility serves as the regional cancer centre for the West of Scotland.

Differentiator

Problem solved

Functional benefit

Products and services

• Radiotherapy Comprehensive radiotherapy treatment services including treatment planning, imaging, radiotherapy physics, and mould room services for precise radiation delivery, for cancer patients referred through NHS Scotland.
• Chemotherapy (Drug Therapy) Systemic cancer treatment using pharmaceutical drugs administered to oncology patients in inpatient and day unit settings (Wards B8 and B9).
• Brachytherapy (Ward B3) Internal radiation therapy delivered through implanted radioactive sources in or near the tumour site, delivered from Ward B3 at the centre.
• PET CT Centre Positron emission tomography combined with CT imaging for cancer diagnosis, staging, and treatment monitoring.
• MRI Scanner Magnetic resonance imaging service for detailed cancer visualization and diagnosis.
• Clinical Apheresis Unit Specialized unit providing photopheresis, lymphocyte donation, and peripheral blood stem cell collection (PBSC) services.
• Clinical Trials Access to experimental treatments and clinical research programmes for eligible cancer patients.
• Palliative Care Specialized care focused on relief from symptoms and stress of serious illness to improve quality of life for cancer patients.
• Interventional Cancer Pain Service Pain management services using interventional techniques for cancer patients.
• Teenage and Young Adult Cancer Service Dedicated cancer care services tailored for teenagers and young adults aged 13–24.
• Cancer Older Peoples Service (COPS) Specialized cancer services for older patients addressing age-related care needs.
• Acute Oncology Assessment Unit (AOAU) Acute oncology assessment service for rapid assessment of cancer-related complications and emergencies.
• Haematology Day Unit (Ward B8) Outpatient services for blood cancer patients requiring day treatment and monitoring.
• Oncology Day Unit (Ward B9) Outpatient chemotherapy and oncology treatment services.
• Inpatient Cancer Wards (B1, B2, B4, B5, B5 ECU, B7) Inpatient wards providing 24-hour specialist cancer care, including an Enhanced Care Unit (ECU) for higher-dependency oncology patients.
• Blenrep (belantamab mafodotin) treatment for multiple myeloma Newly commissioned treatment programme for relapsed or refractory multiple myeloma, available at the Beatson following Scottish Medicines Consortium approval, based on phase 3 data.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• GSK (GlaxoSmithKline)minorStrategic or Co-development PartnerGSK's Blenrep (belantamab mafodotin) treatment was approved by the Scottish Medicines Consortium for use at NHS Scotland facilities including Beatson West of Scotland Cancer Centre for relapsed or refractory multiple myeloma patients.

Recent moves6 records

Expansion highlights4 records

Direct peers

• Velindre University NHS Trust: Welsh NHS specialist cancer centre providing radiotherapy, chemotherapy, and clinical trials — operates a comparable NHS specialist cancer model serving a regional Welsh population.
• The Christie NHS Foundation Trust: UK's largest single-site cancer centre, an NHS specialist oncology hospital providing radiotherapy, chemotherapy, brachytherapy, and clinical trials across Greater Manchester and the North West — directly comparable as a regional NHS oncology hub.
• The Royal Marsden NHS Foundation Trust: Specialist NHS cancer hospital in London and Sutton offering comprehensive inpatient, outpatient, radiotherapy, chemotherapy, and clinical trial services — the closest functional analogue to the Beatson in scope and operating model.
• Clatterbridge Cancer Centre NHS Foundation Trust: NHS specialist cancer centre serving Cheshire, Merseyside and surrounding areas with radiotherapy, chemotherapy, and a long-established clinical trials programme — comparable NHS specialist oncology operator.
• Edinburgh Cancer Centre (Western General Hospital): NHS Scotland specialist cancer centre providing radiotherapy, chemotherapy and clinical trials for South East Scotland — a direct sister facility under NHS Scotland with overlapping oncology service lines.
• Northern Centre for Cancer Care (Newcastle upon Tyne Hospitals): NHS specialist cancer centre serving the North East of England and North Cumbria, offering radiotherapy, chemotherapy, brachytherapy and clinical trials — closely comparable UK NHS regional oncology model.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Major US specialty cancer hospital and research institute with comprehensive oncology services spanning inpatient wards, day units, imaging and clinical trials — a global benchmark for integrated cancer centre operations.
• GenesisCare: Private specialist oncology provider operating radiotherapy and chemotherapy centres across the UK and internationally — comparable as a multi-modality oncology service operator, although commercially rather than NHS-funded.
• MD Anderson Cancer Center: Globally leading academic cancer centre in the US offering comprehensive inpatient and outpatient oncology including radiotherapy, chemotherapy, surgery and clinical trials — broader global benchmark for the Beatson's specialty oncology model.

Emerging players

• Sarah Cannon Research Institute: US-based clinical trial network and oncology research organisation offering early-phase oncology trials — relevant as a comparator for the Beatson's clinical trials research arm and pharma partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nhsscotland

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beatson West of Scotland Cancer Centre